Roche's new-drug strategy buoyed by lung-cancer study

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG, seeking to expand uses for its drug Tecentriq beyond bladder cancer, said on Thursday a study had shown the new immunotherapy helped people with lung cancer live longer than with chemotherapy.